Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background

被引:85
作者
Itti, Emmanuel [1 ,3 ]
Juweid, Malik E. [2 ]
Haioun, Corinne [4 ]
Yeddes, Imene
Hamza-Maaloul, Fatma
El Bez, Intidhar
Evangelista, Eva
Lin, Chieh [5 ,6 ]
Dupuis, Jehan [4 ]
Meignan, Michel [3 ]
机构
[1] Hop Henri Mondor, Assistance Publ Hop Paris, Dept Nucl Med, Nucl Med Serv, F-94010 Creteil, France
[2] Univ Iowa, Div Nucl Med, Iowa City, IA USA
[3] Univ Paris 12, CNRS, EAC 7054, Creteil, France
[4] Hop Henri Mondor, Assistance Publ Hop Paris, Dept Clin Hematol, F-94010 Creteil, France
[5] Chang Gung Mem Hosp & Univ, Dept Nucl Med, Tao Yuan, Taiwan
[6] Chang Gung Mem Hosp & Univ, Mol Imaging Ctr, Tao Yuan, Taiwan
关键词
PET; lymphoma; prognosis; response; POSITRON-EMISSION-TOMOGRAPHY; STAGE HODGKINS LYMPHOMA; SUV-BASED ASSESSMENT; RESPONSE ASSESSMENT; INTERNATIONAL WORKSHOP; FDG-PET; INTERIM; CHEMOTHERAPY; CRITERIA; THERAPY;
D O I
10.2967/jnumed.110.080556
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study investigated whether the reference background above which a residual mass is considered positive in the International Harmonization Project criteria should be modified for early F-18-FDG PET evaluation. Methods: In 92 patients with newly diagnosed diffuse large B-cell lymphoma, the maximal standardized uptake value (SUVmax) was measured on post-cycle 2 PET in the most intense residual mass (or, in the case of negative PET findings, in the area of most intense tumor uptake before therapy), in the mediastinal blood pool (MBP) and the liver, as potential reference background tissues. Results: With MBP as a reference (SUVmax, 2.0 +/- 0.6), PET was unable to distinguish early responders from nonresponders. In contrast, with liver as a reference (SUVmax, 2.5 +/- 0.7), 2-y progressionfree survival was significantly different between patients with PET-negative findings (81.8% [95% confidence interval, 71%-93%]) and patients with PET-positive findings (51.8% [95% confidence interval, 35%-69%], P = 0.003). Conclusion: When assessing early response, particularly in risk-adapted therapeutic trials, it seems preferable to refer to a background tissue (liver) with a higher level of uptake than that of current international criteria (MBP) which were designed for end-of-treatment evaluation.
引用
收藏
页码:1857 / 1862
页数:6
相关论文
共 23 条
[11]   PET/CT for Therapy Response Assessment in Lymphoma [J].
Hutchings, Martin ;
Barrington, Sally F. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 :21S-30S
[12]   Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy [J].
Itti, Emmanuel ;
Lin, Chieh ;
Dupuis, Jehan ;
Paone, Gaetano ;
Capacchione, Daniela ;
Rahmouni, Alain ;
Haioun, Corinne ;
Meignan, Michel .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (04) :527-533
[13]   Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma [J].
Juweid, Malik E. ;
Stroobants, Sigrid ;
Hoekstra, Otto S. ;
Mottaghy, Felix M. ;
Dietlein, Markus ;
Guermazi, Ali ;
Wiseman, Gregory A. ;
Kostakoglu, Lale ;
Scheidhauer, Klemens ;
Buck, Andreas ;
Naumann, Ralph ;
Spaepen, Karoline ;
Hicks, Rodney J. ;
Weber, Wolfgang A. ;
Reske, Sven N. ;
Schwaiger, Markus ;
Schwartz, Lawrence H. ;
Zijlstra, Josee M. ;
Siegel, Barry A. ;
Cheson, Bruce D. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :571-578
[14]   Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue-to-blood background ratio using positron emission tomography in healthy humans [J].
Kanstrup, Inge-Lis ;
Klausen, Thomas Levin ;
Bojsen-Moller, Jens ;
Magnusson, Peter ;
Zerahn, Bo .
CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2009, 29 (02) :108-113
[15]  
Kasamon YL, 2007, J NUCL MED, V48, p19S
[16]   Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma:: SUV-based assessment versus visual analysis [J].
Lin, Chieh ;
Itti, Emmanuel ;
Haioun, Corinne ;
Petegnief, Yolande ;
Luciani, Alain ;
Dupuis, Jehan ;
Paone, Gaetano ;
Talbot, Jean-Noel ;
Rahmouni, Alain ;
Meignan, Michel .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (10) :1626-1632
[17]   Report on the First International Workshop on interim-PET scan in lymphoma [J].
Meignan, Michel ;
Gallamini, Andrea ;
Haioun, Corinne .
LEUKEMIA & LYMPHOMA, 2009, 50 (08) :1257-1260
[18]   Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials [J].
Meignan, Michel ;
Itti, Emmanuel ;
Bardet, Stephane ;
Lumbroso, Jean ;
Edeline, Veronique ;
Olivier, Pierre ;
Vander Borght, Thierry ;
Reman, Oumedaly ;
Karcher, Gilles ;
Mundler, Olivier ;
Mounier, Nicolas ;
Ricci, Romain ;
Federico, Massimo ;
Raemaekers, John ;
Andre, Marc .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2739-2741
[19]   FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma [J].
Mikhaeel, NG ;
Hutchings, M ;
Fields, PA ;
O'Doherty, MJ ;
Timothy, AR .
ANNALS OF ONCOLOGY, 2005, 16 (09) :1514-1523
[20]   18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT [J].
Mikhaeel, NG ;
Timothy, AR ;
O'Doherty, MJ ;
Hain, S ;
Maisey, MN .
LEUKEMIA & LYMPHOMA, 2000, 39 (5-6) :543-553